KDR and neoplasm: In addition, transgenic expression of VEGFR2-specific CARs and IL-12 in T cells was sufficient to eradicate tumors, indicating that overcoming the inhibitory tumor microenvironment might potentiate effects of CAR T-cell therapies (see Section Engineering T-Cell Resistance to Immune Evasion Strategies Employed by GBMs) (69).